Breaking News, Collaborations & Alliances

Alvotech, DKSH Partner to Bring Biosimilar to Asia

Biosimilar of AbbVie’s Humira to be developed and supplied by Alvotech

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alvotech and DKSH have entered into an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected Asia-Pacific markets.   AVT02 is a biosimilar monoclonal antibody to AbbVie’s Humira, which is a leading drug indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease amongst other indications. It neutralizes tumor ne...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters